帕博利珠单抗联合贝伐珠单抗治疗晚期非小细胞肺癌的疗效及对患者血清HIF-1α、VEGF水平的影响  

Efficacy of Palbolizumab Combined with Bevacizumab in the Treatment of Advanced Non-small Cell Lung Cancer and Its Effect on Serum HIF-1α and VEGF Levels

作　　者：郭茜茜 陈偲偲 祝远帅 GUO Qianqian;CHEN Sisi;ZHU Yuanshuai(Department of Oncology,Shandong Guoxin Yiyang Group Zaozhuang Central Hospital,Zaozhuang,Shandong,277000,China)

机构地区：[1]山东国欣颐养集团枣庄中心医院肿瘤科,山东枣庄277000

出　　处：《中外医疗》2025年第1期19-22,共4页China & Foreign Medical Treatment

摘　　要：目的探讨帕博利珠单抗联合贝伐珠单抗治疗晚期非小细胞肺癌的疗效及对患者血清缺氧诱导因子-1α(hypoxia inducible factor 1α,HIF-1α)、血管内皮生长因子水平的影响。方法方便选取2021年4月至2023年4月山东国欣颐养集团枣庄中心医院收治的86例晚期非小细胞肺癌患者作为研究对象,根据不同治疗方法分为两组,各43例。对照组采取常规化疗方案,观察组在常规化疗基础上采取帕博利珠单抗联合贝伐珠单抗治疗。比较两组治疗效果、血清肿瘤标志物水平及不良反应发生率。结果观察组的总有效率为67.44%(29/43)、疾病控制率86.05%(37/43)高于对照组34.88%(15/43)、67.44%(29/43),差异均有统计学意义(χ^(2)=9.121,4.169;P均<0.05)。治疗后,两组患者血清缺氧诱导因子1α、血管内皮生长因子、癌胚抗原、细胞角蛋白19血清片段21-1、鳞状上皮细胞癌抗原水平明显降低,观察组低于对照组,差异均有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论晚期非小细胞肺癌在常规化疗基础上实施帕博利珠单抗联合贝伐珠单抗治疗可取得良好的疗效,降低肿瘤标志物含量,而且增加用药未加重不良反应。Objective To investigate the efficacy of pabolizumab combined with bevacizumab in the treatment of ad-vanced non-small cell lung cancer and its effect on serum levels of hypoxia inducible factor 1α(HIF-1α)and vascu-lar endothelial growth factor.Methods A total of 86 patients with advanced non-small cell lung cancer admitted to Shandong Guoxin Yiyang Group Zaozhuang Central Hospital from April 2021 to April 2023 were convenient to be se-lected as the research objects.According to different treatment methods,they were divided into two groups,with 43 cases in each group.The control group was treated with conventional chemotherapy,and the observation group was treated with paporizumab combined with bevacizumab on the basis of conventional chemotherapy.The therapeutic ef-fect,serum tumor marker level and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 67.44%(29/43),and the disease control rate was 86.05%(37/43),which were higher than those of the control group 34.88%(15/43)and 67.44%(29/43),the differences were statisti-cally significant(χ^(2)=9.121,4.169;both P<0.05).After treatment,the levels of hypoxia inducible factor 1α,vascular en-dothelial growth factor,carcinoembryonic antigen,cytokeratin 19 serum fragment 21-1 and squamous cell carcinoma antigen in the two groups were significantly decreased,and those in the observation group were lower than the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion On the basis of conventional chemotherapy,the treat-ment of advanced non-small cell lung cancer with pabolizumab combined with bevacizumab can achieve good cura-tive effect,reduce the content of tumor markers,and increase the drug without aggravating adverse reactions.

关 键 词：非小细胞肺癌 帕博利珠单抗 贝伐珠单抗 治疗效果 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]